In 271 children and young adults with sickle cell disease acute pain episodes, IV arginine did not shorten median time to crisis resolution vs placebo (60.8 vs 65.8 hours); the trial stopped early for futility, with no differences in opioid use, pain or safety.
RCTn = 274
Morris et al. Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial